The PROactive study: Some answers, many questions

Lancet

Volumn 366, Issue 9493, 2005, Pages 1241-1242

  Yki Järvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; PIOGLITAZONE; PLACEBO;

BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG APPROVAL; DRUG CARCINOGENICITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EDEMA; EUROPE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK REDUCTION; SIDE EFFECT; UNITED STATES; WEIGHT GAIN;

EID: 26244444319     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67504-6     Document Type: Note

References (4)

1. H Yki-Järvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
2. IMS Health, IMS MIDAS http://www.imshealth.com (accessed Sept 28, 2005)
3. JA Dormandy, B Charbonnel, DJA Eckland on behalf of the PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
4. H Yki-Järvinen Combination therapies with insulin in type 2 diabetes Diabetes Care 24 2001 758 767